Skip to main content

Table 2 Primary outcome analysis

From: Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

 

HMB/Arg/Gln

n = 19 N (%)

No HMB/Arg/Gln

n = 19 N (%)

Success (alive without a drop of >5% in LBM)

3 (16)

9 (47)

Failure (alive with a drop of >5% in LBM)

3 (16)

3 (16)

Died

4 (21)

1 (5)

Data not-available

9 (47)

6 (32)

Reasons for unavailable data

 Patient withdrawal

6 (67)

1 (17)

 None attendance at week 12 visit

2 (22)

4 (66)

 Measure not taken

1 (11)

1 (17)

  1. HMB/Arg/Gln β-Hydroxy β-Methylbutyrate/Arginine/Glutamine LBM Lean body mass